What we claim is:

1. A compound of formula (I), wherein



(I)

R^3 represents a substituted or unsubstituted 5- or 6-membered, aromatic, saturated or partially saturated heterocyclic ring containing at least 2 hetero atoms, in which the hetero atom can be oxygen-, sulfur- or nitrogen atom and in the case when the heterocyclic ring contains 2 heteroatoms one of them is different from nitrogen;

R^4, R^5, R^6, and R^7 independently from each other represent hydrogen atom, halogen atom, C_1-C_3 alkyl group, nitro group, amino group, wherein the amino group can be substituted independently from each other with one or two C_1-C_3 alkyl group, C_2-C_5 acyl group, or C_2-C_5 alkoxycarbonyl group, or aminocarbonyl group, or C_2-C_5 alkylaminocarbonyl group,

R^9 represents C_1-C_3 alkoxy group or halogen atom,

R^{10} represents hydrogen or halogen atom or

R^9 and R^{10} together can be C_1-C_3 alkylendioxy group; and

stereoisomers and acid-addition salts of said compound.

2. The compound according to claim 1, wherein the heterocyclic ring of R^3 can be further substituted with one or more C_1-C_5 alkyl group, a C_2-C_3 alkenyl, a C_3-C_7 cycloalkyl, a trifluoromethyl, a C_1-C_3 alkoxy or a phenyl group, an oxo, a formyl, a carboxyl or a C_2-C_4 alkoxycarbonyl group, a C_1-C_3 alkoxymethyl group, a halogen atom, a hydroxymethyl group, wherein the hydroxyl group can be alkylated or acylated, a C_1-C_3 alkylthiomethyl group, a cyanomethyl group or an aminomethyl group, wherein the aminogroup can be alkylated or acylated.

3. The compound according to claim 1, wherein R^3 is selected from the group of substituted and unsubstituted isoxazole, isothiazole, thiazole, thiazoline, 4-thiazolinone, oxazole, oxazoline, 1,2,3-thiadiazole, 1,3,4-thiadiazole, 1,3,4-thiadiazolin-2-one, 1,2,4-thiadiazolin-3-one, 1,4,2-oxathiazoline, 1,3,4-oxadiazole, 1,2,3-triazole, 1,3,4-triazole, 1,2,3,4-thiatriazole, tetrazole, , 1,3-thiazin-4-one and 1,3,4-thiadiazin-4-one ring.

4. The compound according to claim 1, wherein R^3 is a substituted or unsubstituted 1,3,4-thiadiazol-2-yl, 4,5-dihydro-thiazol-2-yl, 2-thiazolyl or 1,3,4-oxadiazolyl group, R^5 is a hydrogen atom or methyl group, R^6 substituent is an amino group, and R^9 and R^{10} represent together a methylenedioxy group, or R^9 is a chlorine atom or methoxy group and R^{10} is a hydrogen or chlorine atom.

5. The compound according to claim 1 selected from the group consisting of (R)-5-(4-aminophenyl)-8-methyl-7-(5-methyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; (R)-5-(4-aminophenyl)-8-methyl-7-(1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; (R)-5-(4-aminophenyl)-8-methyl-7-(2-thiazolyl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; (R)-5-(4-aminophenyl)-7-(4,5-dihydro-thiazol-2-yl)-8-methyl-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; (R)-5-(4-aminophenyl)-7-(5-ethyl-1,3,4-thiadiazol-2-yl)-8-methyl-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; (R)-5-(4-aminophenyl)-8-methyl-7-(5-methyl-1,3,4-oxadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; (R)-5-(4-amino-3-methylphenyl)-8-methyl-7-(5-methyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo-[4,5-h][2,3]benzo-diazepine; (R)-5-(4-Amino-3-methylphenyl)-7-(5-ethyl-1,3,4-thiadiazol-2-yl)-8-methyl-8,9-dihydro-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine; (R)-5-(4-amino-3-methylphenyl)-8-methyl-7-(5-propyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzo-diazepine; (R)-5-(4-amino-3-methylphenyl)-8-methyl-7-(1,3,4-thiadiazol-2-yl)-

8,9-dihydro-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine; (R)-5-(4-amino-3-methylphenyl)-8-methyl-7-(5-methoxymethyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo-[4,5-h][2,3]benzo-diazepine; (R)-5-(4-amino-3-methylphenyl)-8-methyl-7-{5-[1-(1E)-propen-1-yl]-1,3,4-thiadiazol-2-yl}-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine; (R)-5-(4-amino-3-chlorophenyl)-8-methyl-7-(5-methyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine; and (R)-5-(4-amino-3-chlorophenyl)-8-methyl-7-(5-methoxy-methyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine and the acid addition salts thereof.

6. The compound according to claim 1, wherein the compound is (R)-5-(4-amino-3-methylphenyl)-8-methyl-7-(5-methyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine or the addition salt thereof.

7. The compound according to claim 1, wherein the compound is (R)-5-(4-amino-3-methylphenyl)-7-(5-ethyl-1,3,4-thiadiazol-2-yl)-8-methyl-8,9-dihydro-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine or the acid addition salt thereof.

8. The compound according to claim 1, wherein the compound is (R)-5-(4-amino-3-methylphenyl)-8-methyl-7-(5-propyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine or the acid addition salt thereof.

9. The compound according to claim 1, wherein the compound is (R)-5-(4-amino-3-methylphenyl)-8-methyl-7-(1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine or the acid addition salt thereof.

10. The compound according to claim 1, wherein the compound is (R)-5-(4-amino-3-methylphenyl)-8-methyl-7-(5-methoxymethyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine or the acid addition salt thereof.

11. The compound according to claim 1, wherein the compound is (R)-5-(4-amino-3-methylphenyl)-8-methyl-7-{5-[1-(1E)-propen-1-yl]-1,3,4-thiadiazol-2-yl}-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine or the acid addition salt thereof.

12. The compound according to claim 1, wherein the compound is (R)-5-(4-amino-3-chlorophenyl)-8-methyl-7-(5-methyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo-[4,5-h][2,3]benzodiazepine or the acid addition salt thereof.

13. The compound according to claim 1, wherein the compound is (R)-5-(4-amino-3-chlorophenyl)-8-methyl-7-(5-methoxymethyl-1,3,4-thiadiazol-2-yl)-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine or the acid addition salts thereof.

14. A pharmaceutical composition, comprising a compound of formula (I) according to any one of claims 1 to 14, or a stereoisomer or a pharmaceutically acceptable salt thereof.

15. A method for treating glutamate dysfunction associated with an acute or chronic neurodegenerative disease, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1.

16. The method of claim 8, wherein the neurodegenerative disease is selected from the group consisting of cerebral ischemia (stroke), brain and spinal cord trauma, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, AIDS-induced dementia, essential tremor, Parkinson's disease, multiple sclerosis and urinary incontinence.

17. A method for treating epilepsy comprising administering to a subject in need of such treatment a therapeutically effective antiepileptic amount of a compound of claim 1.

18. A method for reducing muscle spasms comprising administering to a subject in need of such treatment a therapeutically effective muscle relaxing amount of a compound of claim 1.

19. A method for treating acute and chronic inflammatory disorders, comprising administering to a mammal in need of such treatment a therapeutically effective anti-inflammatory amount of a compound of claim 1.

20. The method of claim 19 wherein the inflammatory disorder treated is an allergic inflammatory disorder of the airways.

21. The method of claim 20 wherein the allergic inflammatory disorders of the airways is selected from the group consisting of allergic rhinitis, intrinsic or extrinsic asthma bronchiale, acute or chronic bronchitis, chronic obstructive pulmonary disease and pulmonary fibrosis.

22. A method for relief of pathological pain comprising administering to a subject in need of such treatment a pain reducing therapeutically effective amount of a compound of claim 1.

23. A method for treating glutamate dysfunction in acute or chronic disease of the eyes associated with glutamate dysfunction, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 1.

24. The method of claim 23, wherein the disease treated is selected from glaucoma or diabetic retinopathy.